RNA

#circular RNAs #Phase I trial #RiboX Therapeutics #RNA

First circular RNA begins trials in radiation-induced xerostomia

RiboX Therapeutics has dosed the first patient in its first-in-human (FIH) Phase I/IIa clinical trial (SPRINX-1) evaluating the safety and efficacy of RXRG001 in patients with radiation-induced-xerostomia (RIX) and hyposalivation.  RXRG001 is the first circular RNA therapy to receive FDA IND clearance.  Xerostomia and hyposalivation… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Cancer research #DNA #Genetics / genomics #Oncology #RNA #siRNA

New podcast: The revolutionary impact of understanding genomics

This is the latest episode of the free DDW narrated podcast, titled “The revolutionary impact of understanding genomics”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Open science, genomics, and the quiet revolution in our approach to pharma” and “… Read More

#News

European Union and African Union flags
#Biologics #Collaboration #Immunology / Virology & Vaccines #mRNA-based vaccines #RNA

African European alliance to advance RNA-based vaccines

A new African European collaboration aims to develop the first ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines.  A Memorandum of Understanding was signed by Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences during the… Read More

#News

RNA strand
#Akribion Therapeutics #Oncology #RNA #Seed funding #Start-ups

€8m financing to pioneer RNA-guided cell depletion 

Akribion Therapeutics has exited stealth mode and completed a seed financing round, raising €8 million to accelerate the development of novel therapeutics.  The round was led by CARMA FUND and RV Invest, with investments from MP Beteiligungs, Hessen Kapital I, Bruker Invest and High-Tech Gründerfonds. … Read More

#Business & Investment #Cancer Research #News #Start-up Zone

#Antisense Oligonucleotides (ASOs) #Gene expression #Genetics / genomics #RNA

Antisense oligonucleotides: Navigating ethical and safety challenges

Tina Rogers, Senior Technical Director, Toxicology at WuXi AppTec, discusses the ethical and safety challenges of developing antisense oligonucleotides. Antisense oligonucleotides (ASOs) have emerged as a promising class of therapeutics, offering unique mechanisms to target and silence disease-causing genes. Unlike traditional small molecules or biologics, ASOs work by binding to… Read More

#Exclusive Content

#Artificial intelligence (AI) #Drug development #Drug discovery #Omics #RNA

Omics, mRNA and AI: Your top 10 reads of 2024

What were the trending topics of the year? Here, we run through DDW’s most read articles of 2024. 10: The future outlook for mRNA therapies In this article for the Spring 2024 issue, DDW Editor Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. 9: Key… Read More

#News

mRNA
#Circio Holding #circular RNAs #DNA #Funding #mRNA #Norway #RNA #Viral vectors

NOK 10.7 million supports circular mRNA technology

Biotechnology company Circio Holding has secured approximately NOK 10.7 million (€907.4k) in financing to support the development of its circVec circular mRNA technology. The major allocations in the financing were to existing shareholders Høse AS and Bækkelaget Holding AS, and new shareholders Star Kapital AS (v/ Tom A Thorsen) and… Read More

#News

DDW mRNA eBook cover
#eBook #mRNA #mRNA-based vaccines #RNA #tRNA

mRNA: Uses and innovation for this technology in drug discovery

This eBook, sponsored by Promega, examines the latest innovations that are driving the mRNA drug discovery and development market. Download this exclusive eBook to learn more about: Recent developments in mRNA drug discovery Using AI to design RNA-based medicines The evolution of the RNA therapeutics landscape Using tRNA to treat… Read More

#DDW eBooks #Intelligence

#eBook #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #RNA #tRNA

eBook: mRNA innovation in drug discovery

The success of mRNA-based vaccines for Covid-19 pushed messenger RNA into the spotlight. However, its uses in drug discovery and development aren’t just confined to vaccines – applications include personalised medicine and therapeutics, for example. This eBook, sponsored by Promega, examines the latest innovations that are… Read More

#News

Transfer RNA
#Alltrna #Flagship Pioneering #Mouse models #Oligonucleotides #Rare disease #RNA #tRNA

First tRNA development candidate restores protein production

Data demonstrate that engineered tRNA from Alltrna’s first development candidate restores protein production to clinically meaningful levels in two disease models driven by the same premature termination codon.  AP003 is a chemically modified, engineered tRNA oligonucleotide in a clinically validated, liver-directed lipid nanoparticle (LNP) that can readthrough… Read More

#News

Human heart
#Cardiovascular disease #Heart disease #Phase II trial #RNA #Silence Therapeutics

Silence Therapeutics presents late-breaking Phase II data at AHA

Biotechnology company Silence Therapeutics has shared end-of-treatment data from its Phase II ALPACAR-360 study of short interfering RNA (siRNA) zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein levels. These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific… Read More

#News

#Genetics / genomics #mRNA #Rare disease #RNA

How mRNA’s tiny cousin could treat thousands of rare diseases

DDW Editor Reece Armstrong speaks to Dr Caroline Kӧhrer, Vice President, Discovery Platform, Alltrna, about the biology behind tRNAs and how they could help produce a medicine that could treat thousands of rare diseases that share the same genetic mutation. RA: Why are tRNA molecules so important for rare genetic… Read More

#Exclusive Content

Cell and gene therapy concept
#Cell and gene therapy #Cell therapy #Gene therapy #RNA

What are the challenges and advancements driving CGT drug development?

In this webinar you will hear from Erik Wiklund, CEO of Circio, Ali Pashazadeh, CEO of Treehill Partners, and Gerard Caelles, CBO at Splice Bio. Erik Wiklund will discuss how circular RNA is crucial to the development of next-generation cell and gene therapy products. Ali Pashazadeh will explore current barriers… Read More

Webinar date:
Sponsored by Benchling and Applied StemCell
#Webinars

Victor Ambros and Gary Ruvkun
#Genetics / genomics #Karolinska Institutet #microRNAs #Nobel Prize #RNA

Ambros and Ruvkun receive Nobel Prize for microRNA discovery

The Nobel Assembly at Karolinska Institutet has awarded the 2024 Nobel Prize in Physiology or Medicine jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. Victor Ambros is Silverman Professor of Natural Science at the University… Read More

#News

RNA
#CRISPR #Gene editing #Genetics / genomics #Interview #RNA #University of Sydney

Beyond CRISPR – what a new tool offers gene editing

DDW Editor Reece Armstrong speaks to Dr Sandro Ataide, Senior Lecturer in Structural Biology at the School of Life and Environmental Sciences Sydney Drug Discovery Initiative (DDI). Earlier this year, Dr Ataide’s team developed a gene-editing tool called SeekRNA that uses a programmable ribonucleic acid (RNA) strand that can… Read More

#Exclusive Content

#Cell and gene therapy #Cell therapy #Gene therapy #RNA #Webinar

Webinar: Understand the challenges and advances driving CGTs

In this webinar on 8 October 3-4PM BST, hosted by DDW and sponsored by Benchling, you will learn about the challenges and advancements driving drug development for cell and gene therapies. You will hear from Erik Wiklund, CEO of Circio, Ali Pashazadeh, CEO of Treehill Partners, and… Read More

Webinar date:
Sponsored by Benchling
#News